biotechnolog high convict posit explor outcom heart-to-heart cardiologist
medic suppli devic nan takeaway new wave innov could stimul scs/db market growth move
consum assess restaur exposur china amid coronaviru travel restrict
biotechnolog pubm pregam immun respons thing
biotechnolog phacilit field report gene therapi manufactur slow progress made challeng
 power forward power curv genco mtm weekli commentari
page analyst certif import disclosur
biotechnolog sickl cell survey suggest rapid uptak oxbryta adakveo
anim health vmx takeaway look bring disrupt parasiticid consum channel
aliv news shanghai disneyland close lunar new year prevent spread coronaviru snap
hire new exec docu-seri unscript origin
publish januari
messag start new year new outlook renew storag opportun reiter guidanc confid
playbook report headlin ep miss believ stori remain top-of-the-rang ep grower renew angl abil
execut upsid opportun regul unregul busi develop pipelin nep also report slight miss ye
ebitda track run rate ebitda target per management need acquisit reach distribut target see
need /nep chang strategi execut current continu trend peer reiter buy nep adjust pt
base slightli reduc estim
sickl cell survey suggest rapid uptak oxbryta
publish januari
messag takeaway sickl cell survey poll hematolog kol includ physician higher-than-expect us
buy-sid level familiar oxbryta novn adakveo despit myriad safety/toler issu current hydroxyurea
page analyst certif import disclosur
usag rel high view hydroxyurea popul good proxi target oxbryta/adakveo use survey suggest faster
uptak drug oxbryta script heavili focus patient hematolog symptom adakveo script focus patient
pain crise hospit new patient start oxbryta could eclips scd patient l-t market share like rang
adakveo oxybryta combo could see usag scd patient gene therapi cur potenti current precondit
requir may limit usag overal survey made us increment confid oxbryta adakveo uptak scd market place
two compound unlik see much direct competit reiter buy rate increas pt
ep guidanc like receiv
publish januari
messag ep yoy rel line vs fx-adj revenue grew healthi yoy modestli
forecast growth bill busi vs lend vs moder came slightli
expect importantli think guidanc fx-adj revenue ep well receiv investor believ
commentari rise engag achiev pariti coverag bode well go forward remain neutral larg valuat
ep risk/reward look balanc follow share recent out-performance sinc vs
 high convict posit explor outcom
publish januari
messag reiter buy rate ahead pivot data lead program patient hypertroph cardiomyopathi hcm
follow survey us cardiologist current treat hcm patient overal cardiologist comfort explor trial design
well likelihood posit efficaci outcom support high convict clinic meaning benefit mavacamten heart
failur popul addit respons safeti particularli cardiovascular safeti efficaci outcom help frame bull/bear case scenario
analysi highlight
page analyst certif import disclosur
updat cardiologist survey result bode onpattro
publish januari
messag recent publish result new attr-cm hcm survey conduct dec cardiologist result avail
compar result prior attr survey cardiologist survey june takeaway result larg similar
small possibl import shift think bode well use onpattro cardio set
nan takeaway new wave innov could stimul scs/db market growth move share
publish januari
messag year nan confer one event neuromodul meet time almost everi compani
space highlight excit new product intrigu dataset suggest potenti improv patient outcom across exist new
indic time db market somewhat starv growth believ fresh wave innov could spark
resurg implant volum shake market share walk key takeaway major competitor
assess restaur exposur china amid coronaviru travel restrict coverag
publish januari
messag anticip travel restrict heighten awar relat coronaviru disrupt consum behavior near term
advers affect consum demand inclus restaur spend region within coverag univers report
mcdonald announc store close china relat viru estim compani oper model
china greatest exposur measur percentag ww system revenu oper incom follow domino
also see risk year growth goal could impair new store develop could disrupt china repres high growth region
meaning contributor long-term global revenu growth goal three compani lastli chines new year celebr span
januari februari year histor accompani strong consum demand celebr thu could
lost demand leav estim unchang await updat manag guidanc within context upcom earn confer
page analyst certif import disclosur
publish januari
messag week publish updat hcm softwar industri downgrad altair share view post
earn announc new guggenheim confer call event next week hcm softwar industri updat includ price target revis
hcm coverag well downgrad buy neutral slow growth believ could exacerb
ceo transit also downgrad altair neutral sell share trade level despit report weak underli
busi see potenti risk result under-perform consensu expect revenu gener auto
seen declin sale deceler capital-expenditure report better-than-expect result increas guid due strong quarter
posit fx benefit
host confer call tuesday januari et guggenheim analyst ken wong former chief innov offic
 block inc also presid tax softwar divis oversaw intern free file allianc ffa polici call focu
relationship ir tax solut provid ffa competit dynam mou modifi impact technolog
chang assist tax prep market thought industri trend head tax season
novo rybelsu launch back track earli launch
publish januari
messag rybelsu ad /week nrx prescript date continu driven
specialist high trx/hcp per novo pcp fm/im/np/pa low trx/hcp presum novo gener
co-pay card program continu expect earli revenu contribut rybelsu modest novo lay foundat
rybelsu access reimburs novo franchis victoza ozemp rybelsu remain market share leader share vs
trulic share
pubm pregam immun respons thing
publish januari
messag big chunk pregam virus avoid immun respons context gene therapi
heavi flu season new coronaviru worri remind sometim immun respons viru good thing
enter vaccin week sever vaccin compani announc program combat new viru one approach info use mrna
page analyst certif import disclosur
mimic viral replic induc immun respons without requir live inactiv virus week paper author evalu trans-
amplifi mrna-bas approach found outperform non-repl mrna self-amplifi mrna approach mice
buy posit read-through phase
result gi
publish januari
messag announc updat phase data asco-gi view bode well success probabl
on-going phase trial w/ rog-ch schedul read updat cabometyx opdivo efficaci see
enclos tabl includ month mo mix popul mo reach cabometyx opdivo yervoy cohort
compar well vs month seen previous sever frontlin nexavar phase trial compar arm cosmic maintain buy
pipelin shift back focu compani kick data-fil
phacilit field report gene therapi manufactur slow progress made challeng remain
publish januari
messag week attend phacilit confer focus attent cell gene therapi manufactur session
rel last year discuss around aav capac constraint challeng year almost entir focus lentiviru
capac constraint cell therapi manufactur challeng overcom key hurdl space evolv rapidli progress made
perhap quickli clinic develop timelin move one panelist note develop cell gene therapi like fli
plane build balanc lock certain process earli get ball roll form regulatori perspect also constantli tri
tweak/optim process go addit takeaway week
forward power curv genco mtm weekli commentari
publish januari
weekli power capac market polici highlight guggenheim takeaway page report
messag week week basi nation atc spark spread lower region lower iso-n lead
way follow miso pac northwest respect ercot move lower atc power price
lower across iso averag iso-n nyiso miso pjm lose ercot market
averag respect natur ga price move lower throughout countri henri hub price decreas
region region texa
power spark spread slight neg impact ipp genco mark vs decemb mark modestli
page analyst certif import disclosur
publish januari
guggenheim host client util event ndr schedul scroll
util outlook ride cyclic wave crash bond proxi select pick name wise see
energi servic report competit review process
file joint settlement centerpoint houston rate case term conform prior disclosur puct discret financi ring-fenc
dominion receiv notic decis ncuc regard coal ash cost recoveri
ny attorney gener voic concern indian point decommiss licens transfer
appalachian power issu rfp mw solar va
njr/sji/so ferc hear regard penneast push next week
sr environment group sue ferc pipelin approv
ferc busi open meet glick lament roe methodolog headach mcname seek anoth term
ferc/pjm ferc put temporari hold fast start pjm iron kink
commission kennedi comment ap clean goal
iso-n nepga pen ope call market-bas decarbon mechan
vmx takeaway look bring disrupt parasiticid consum channel
publish januari
messag attend vmx confer host lunch former abaxi ceo clint severson believ invest takeaway
around zoeti parasiticid market converg vet pet highlight zoeti mild advertis lack
competit threat consum side willing chewi commun vet directli suggest acceler vet/pet paradigm
believ two less invest trend watch longer term excit surround emerg small privat pim compani
cytolog instrument think investor watch view less action either posit neg side right
page analyst certif import disclosur
daili invest futur growth hcm softwar growth premium aliv news shanghai
disneyland close lunar new year prevent spread coronaviru snap hire new exec docu-seri
publish januari
mccormack lower price target compani temper outlook nbcu rais invest expect
hcm softwar amladi see growth premium hcm coverag healthi employ backdrop updat valuat analysi across coverag
downgrad neutral
page analyst certif import disclosur
inc
page analyst certif import disclosur
primari analyst jake fuller
page analyst certif import disclosur
primari analyst glen santangelo
page analyst certif import disclosur
explor product
page analyst certif import disclosur
primari analyst michael schmidt
primari analyst etzer darout
life scienc tool omic
primari analyst david westenberg cfa
page analyst certif import disclosur
